Martine Van Vugt

USPTO Granted Patents = 13 (Patent Applications = 8)

CIPO Patents = 2

EPO Patents = 14 (Patent Applications = 10)

Average Co-Inventor Count = 10.5

ph-index = 8

Forward Citations = 309(Granted Patents)

Company Filing History:

6 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2009-2015

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9187565 - Antibodies against CD38 for treatment of multiple myeloma (2015-11-17),

2. 9102733 - Anti-OX40L antibodies (2015-08-11),

3. 9040050 - Combination treatment of CD38-expressing tumors (2015-05-26),

4. RE44389 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2013-07-22),

5. RE44359 - Nucleic acid molecules encoding anti-P-selectin antibodies (2013-07-08),

6. RE43568 - Anti-P-selectin antibodies (2012-08-06),

7. 7868141 - Anti-OX40L antibodies (2011-01-11),

8. 7829673 - Antibodies against CD38 for treatment of multiple myeloma (2010-11-09),

9. 7824684 - Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies (2010-11-02),

10. 7807158 - Antibodies against IL-13 receptor alpha1 and uses thereof (2010-10-05),

11. 7754867 - Nucleic acid molecules encoding anti-P-selectin antibodies (2010-07-13),

12. 7563441 - Anti-P-selectin antibodies (2009-07-21),

13. 7501496 - Anti-OX40L antibodies (2009-03-10),

Title: The Innovative Contributions of Martine Van Vugt in the Field of Antibodies

Introduction: Martine Van Vugt, based in Houten, Netherlands, is a prominent inventor renowned for his significant contributions to the field of biotechnology. With a total of 13 patents to his name, he has made substantial advancements in the treatment of diseases through innovative antibody designs.

Latest Patents: Among his notable recent patents are the following:

1. **Antibodies against CD38 for the Treatment of Multiple Myeloma**: This patent includes isolated human monoclonal antibodies that bind to human CD38 and related antibody-based compositions. Furthermore, it encompasses pharmaceutical compositions with these human antibodies and outlines therapeutic and diagnostic methods for their application.

2. **Anti-OX40L Antibodies**: This invention focuses on anti-OX40L antibodies, particularly those variants that possess a human-derived Fc part and do not interact with complement factor C1q. These antibodies exhibit novel properties providing therapeutic benefits for patients with inflammatory diseases.

Career Highlights: Martine has worked with prestigious companies such as Hoffmann-La Roche Inc. and Roche Palo Alto LLC, where he has collaborated on numerous projects that emphasize his expertise in antibody development. His work at these companies has played a critical role in the advancement of therapeutic strategies against complex diseases.

Collaborations: Throughout his career, Martine has partnered with esteemed colleagues Yvo Graus and Paul Parren. Their collaboration has led to groundbreaking innovations and has further strengthened the impact of their combined expertise on the biotechnology field.

Conclusion: Martine Van Vugt's contributions to antibody research and development are noteworthy and continue to influence therapeutic approaches in medical science. With his extensive patent portfolio and collaborative work, he remains a pivotal figure in the advancement of innovative treatments for various diseases.

This text is generated by artificial intelligence and may not be accurate.